The evidence keeps mounting that these so-called "bone-sparing" drugs are the complete opposite.
What these reports of terrible injury do not tell you is that most of these elderly women do not survive these fractures: They develop pneumonia and die.
It is outrageous that these drugs continue to be advertised on prime time television in New Zealand and doctors continue to dish these out like lollies to unsuspecting and trusting patients.
When there is so much increasing doubt about their safety there should be a moratorium on prescribing them.
If in doubt - Leave it out!
Researchers Find Increased Number Of Low-Energy Subtrochanteric Fractures For A Period Ten Years After Introduction Of Fosamax In That Country
(Posted by Tom Lamb at DrugInjuryWatch.com)
At the Orthopaedic Proceedings section of the Journal of Bone & Joint Surgery, British Volume, web site there is an item that presents some findings from a recent Australian study which supports the apparent link between Fosamax and atypical femur fractures.
This new Fosamax research item is "Femoral Insufficiency Fracture Associated With Prolonged Alendronate Therapy". From the Abstract for this item we get these five key findings about femur fractures in long-term users of Fosamax:
- Of the 41 patients with subtrochanteric insufficiency fracture, 40 (98%) had been taking [Fosamax (alendronate)] and one had been taking risedronate.
- Twenty-nine of the 41 (71%) complained of prodromal pain in the affected femur.
- The mean duration of [Fosamax (alendronate)] use in those with insufficiency fracture was 7.1 years.
- This is the largest study in the literature on subtrochanteric insufficiency fractures and [Fosamax (alendronate)] therapy.
- Confirming recent reports, [Fosamax (alendronate)] use was strongly suggestive of subtrochanteric insufficiency fracture.
These Australian study findings seem consistent with two May 2012 Archives of Internal Medicine articles concerning a study out of Switzerland which found that the use of Fosamax as well as several other bisphosphonates seems to be associated with an increased risk of atypical fractures of the femur, which risk may be determined by the duration of Fosamax treatment. Those two medical journal articles are:
To date, more than a thousand Fosamax - femur fracture lawsuits have been filed against Merck, and more such drug injury legal compensation case filings are expected in the months to come.
|
Text
_______________________________________
The advice in these articles is given freely without promise or obligation. Its all about giving you and your family the tools and information to take control of your health and fitness.
No comments:
Post a Comment